Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial

Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial

  • September 15, 2026

Sling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease through a phase 3 trial and hopefully on to commercialization.

Leave A Comment

Fields (*) Mark are Required